The aim of this study was to evaluate cost structure and rationality of pharmacotherapy of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a pulmonology department of a multiprofile Krasnoyarsk hospital in 2014. Methods. This was a retrospective 1-year study evaluating pharmacotherapy of AECOPD according to electronic medical reports. Medication therapy and frequency of administration of certain drugs were evaluated using frequency analysis. Rationality of medication therapy and treatment expenses were analyzed with ABC/VEN analysis. Results. One hundred and thirty one electronic medical reports were analyzed. Frequency analysis showed that all patients received the combined bronchodilator Berodual and the expectorant bromhexine. Moreover, 81.7% of patients received antibiotics, 75.6% received systemic steroids and 41.2% received inhaled corticosteroids. This is consistent with current scientific trends and recent recommendations. ABC/VEN-analysis showed a rational pharmacotherapy expenditure of funds in patients with AECOPD. The main expenses were associated with vital drugs (58.2%) followed by pharmacotherapy of comorbidity (41.8%) which was administered to 87.8% of the patients. Anticoagulants had the highest cost (22.5% of the total pharmacotherapy of AECOPD). Second-line drugs were not used in the treatment of AECOPD. Conclusion. The main portion of cost of AECOPD pharmacotherapy was related to pathogenic treatment followed by treatment for comorbidity and prevention as the former greatly effects severity and outcomes of COPD.
原文链接
分享
引用
